Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 1/2010

01-01-2010 | Article

Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci

Authors: E. A. Ahmed, T. A. Penfound, S. C. Brewer, P. A. Tennant, E. Y. Chiang, J. B. Dale

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Previous studies in our laboratory described a new group A streptococcal protective antigen (Spa) in type 18 streptococci that was distinct from the type 18 M protein. This study was undertaken to identify additional serotypes of group A streptococci that express Spa proteins. PCR techniques were used to identify and clone a new spa gene from type 36 streptococci. The 5′ sequence of spa36 was highly variable compared to spa18, while the 3′ sequence was conserved. Antisera against Spa36 opsonized type 36 streptococci but not type 18 streptococci, indicating that the opsonic Spa epitopes were type-specific. Antisera against the conserved carboxy-terminal half of Spa18 were used to identify Spa or Spa-like proteins expressed on the surface of 25 of 70 different serotypes of GAS. Spa proteins may represent a new family of type-specific surface antigens that function in concert with M proteins to elicit protective immune responses.
Literature
1.
go back to reference Stevens DL (1999) The flesh-eating bacterium: what’s next? J Infect Dis 179:366–374CrossRef Stevens DL (1999) The flesh-eating bacterium: what’s next? J Infect Dis 179:366–374CrossRef
2.
go back to reference Lancefield RC (1962) Current knowledge of the type specific M antigens of group A streptococci. J Immunol 89:307–313PubMed Lancefield RC (1962) Current knowledge of the type specific M antigens of group A streptococci. J Immunol 89:307–313PubMed
3.
go back to reference Podbielski A, Schnitzler N, Beyhs P, Boyle MDP (1996) M-related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes. Molec Micro 19:429CrossRef Podbielski A, Schnitzler N, Beyhs P, Boyle MDP (1996) M-related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes. Molec Micro 19:429CrossRef
4.
go back to reference Courtney HS, Hasty DL, Dale JB (2003) Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun 71(9):5097–5103CrossRefPubMed Courtney HS, Hasty DL, Dale JB (2003) Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun 71(9):5097–5103CrossRefPubMed
5.
go back to reference Dale JB, Washburn RG, Marques MB, Wessels MR (1996) Hyaluronate capsule and surface M protein in resistance to phagocytosis of group A streptococci. Infec Immun 64:1495–1501 Dale JB, Washburn RG, Marques MB, Wessels MR (1996) Hyaluronate capsule and surface M protein in resistance to phagocytosis of group A streptococci. Infec Immun 64:1495–1501
6.
go back to reference Ji Y, Schnitzler N, DeMaster E, Cleary P (1998) Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes. Infect Immun 66(11):5399–5405PubMed Ji Y, Schnitzler N, DeMaster E, Cleary P (1998) Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes. Infect Immun 66(11):5399–5405PubMed
7.
go back to reference Courtney HS, Bronze MS, Dale JB, Hasty DL (1994) Analysis of the role of M24 protein in streptococcal adhesion and colonization by use of omega-interposon mutagenesis. Infect Immun 62:4868PubMed Courtney HS, Bronze MS, Dale JB, Hasty DL (1994) Analysis of the role of M24 protein in streptococcal adhesion and colonization by use of omega-interposon mutagenesis. Infect Immun 62:4868PubMed
8.
go back to reference Moses AE, Wessels MR, Zalcman K, Alberti S, Natanson-Yaron S, Menes T, Hanski E (1997) Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A streptococcus. Infect Immun 65:64PubMed Moses AE, Wessels MR, Zalcman K, Alberti S, Natanson-Yaron S, Menes T, Hanski E (1997) Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A streptococcus. Infect Immun 65:64PubMed
9.
go back to reference Dale JB, Chiang EY, Liu SY, Courtney HS, Hasty DL (1999) New protective antigen of group A streptococci. J Clin Invest 103:1261–1268CrossRefPubMed Dale JB, Chiang EY, Liu SY, Courtney HS, Hasty DL (1999) New protective antigen of group A streptococci. J Clin Invest 103:1261–1268CrossRefPubMed
10.
go back to reference McLellan DG, Chiang EY, Courtney HS, Hasty DL, Wei SC, Hu MC, Walls MA, Bloom JJ, Dale JB (2001) Spa contributes to the virulence of type 18 group A streptococci. Infect Immun 69(5):2943–2949CrossRefPubMed McLellan DG, Chiang EY, Courtney HS, Hasty DL, Wei SC, Hu MC, Walls MA, Bloom JJ, Dale JB (2001) Spa contributes to the virulence of type 18 group A streptococci. Infect Immun 69(5):2943–2949CrossRefPubMed
11.
go back to reference Caparon MG, Scott JR (1991) Genetic manipulation of pathogenic streptococci. Methods Enzymol 204:556–586CrossRefPubMed Caparon MG, Scott JR (1991) Genetic manipulation of pathogenic streptococci. Methods Enzymol 204:556–586CrossRefPubMed
12.
go back to reference Hall MA, Stroop SD, Hu MC, Walls MA, Reddish MA, Burt DS, Lowell GH, Dale JB (2004) Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun 72(5):2507–2512CrossRefPubMed Hall MA, Stroop SD, Hu MC, Walls MA, Reddish MA, Burt DS, Lowell GH, Dale JB (2004) Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun 72(5):2507–2512CrossRefPubMed
13.
go back to reference Smoot JC, Barbian KD, Van Gompel JJ, Smoot LM, Chaussee MS, Sylva GL, Sturdevant DE, Ricklefs SM, Porcella SF, Parkins LD, Beres SB, Campbell DS, Smith TM, Zhang Q, Kapur V, Daly JA, Veasy LG, Musser JM (2002) Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc Natl Acad Sci U S A 99(7):4668–4673CrossRefPubMed Smoot JC, Barbian KD, Van Gompel JJ, Smoot LM, Chaussee MS, Sylva GL, Sturdevant DE, Ricklefs SM, Porcella SF, Parkins LD, Beres SB, Campbell DS, Smith TM, Zhang Q, Kapur V, Daly JA, Veasy LG, Musser JM (2002) Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc Natl Acad Sci U S A 99(7):4668–4673CrossRefPubMed
14.
go back to reference Dale JB, Beachey EH (1986) Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein. J Exp Med 163:1191–1202CrossRefPubMed Dale JB, Beachey EH (1986) Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein. J Exp Med 163:1191–1202CrossRefPubMed
15.
go back to reference Beachey EH, Stollerman GH, Chiang EY, Chiang TM, Seyer JM, Kang AH (1977) Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of the type 24 M antigen. J Exp Med 145:1469–1483CrossRefPubMed Beachey EH, Stollerman GH, Chiang EY, Chiang TM, Seyer JM, Kang AH (1977) Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of the type 24 M antigen. J Exp Med 145:1469–1483CrossRefPubMed
16.
go back to reference Dale JB, Beachey EH (1985) Multiple heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med 161:113–122CrossRefPubMed Dale JB, Beachey EH (1985) Multiple heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med 161:113–122CrossRefPubMed
17.
go back to reference Timoney JF, Artiushin SC, Boschwitz JS (1997) Comparison of the sequences and functions of Streptococcus equi M-like proteins SeM and SzPSe. Infect Immun 65:3600–3605PubMed Timoney JF, Artiushin SC, Boschwitz JS (1997) Comparison of the sequences and functions of Streptococcus equi M-like proteins SeM and SzPSe. Infect Immun 65:3600–3605PubMed
18.
go back to reference Courtney HS, Hasty DL, Dale JB (2006) Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein. Mol Microbiol 59(3):936–947CrossRefPubMed Courtney HS, Hasty DL, Dale JB (2006) Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein. Mol Microbiol 59(3):936–947CrossRefPubMed
19.
go back to reference McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB (2005) Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41(8):1114–1122CrossRefPubMed McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB (2005) Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41(8):1114–1122CrossRefPubMed
20.
go back to reference Veasy LG, Tani LY, Daly JA, Korgenski K, Miner L, Bale J, Kaplan EL, Musser JM, Hill HR (2004) Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics 113(3 Pt 1):e168–172CrossRefPubMed Veasy LG, Tani LY, Daly JA, Korgenski K, Miner L, Bale J, Kaplan EL, Musser JM, Hill HR (2004) Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics 113(3 Pt 1):e168–172CrossRefPubMed
Metadata
Title
Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci
Authors
E. A. Ahmed
T. A. Penfound
S. C. Brewer
P. A. Tennant
E. Y. Chiang
J. B. Dale
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2010
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-009-0819-0

Other articles of this Issue 1/2010

European Journal of Clinical Microbiology & Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.